Show results for
Refine by
Clinical Trial Program Services In Germany
10 services found
by:Vetter based inRavensburg, GERMANY
Learn how we work with you to design a flexible, scalable, reproducible, and efficient manufacturing processes for your clinical ...
Manufactured by:Minaris Regenerative Medicine, LLC based inAllendale, NEW JERSEY (USA)
Regardless of the type of cell therapy product or the medical indication, the production of cell-based therapeutics is highly complex. Minaris Regenerative Medicine offers you comprehensive manufacturing experience, fully compliant with the relevant regional regulatory requirements of our global facilities in North America, Europe, and ...
Manufactured by:Exosome Diagnostics, Inc. based inWaltham, MASSACHUSETTS (USA)
Exosome Diagnostics partners with biopharma companies and Clinical Centers of Excellence to facilitate biomarker discovery programs in support of early discovery, translational, and clinical programs that may have companion diagnostic development needs. ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Graft Versus Host Disease (GvHD) is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells may identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 days following the transplantation. The GvHD market is predicted to exceed $500 million ...
by:Vetter based inRavensburg, GERMANY
Explore how we transform your API into a supply of high-quality clinical material for your ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Pluristem’s goal is to provide patients, physicians and healthcare systems around the globe with standardized, easy to use and highly effective PLX cell products that need no genetic or tissue matching prior to administration. We are active with many respectful regulatory agencies worldwide to advance our clinical programs towards marketing. Part of our clinical development strategy is to ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
COVID-19 is caused by infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause clusters of severe respiratory illness associated with the need for intensive care unit (ICU) admission and high mortality. Studies have shown that Acute Respiratory Distress Syndrome (ARDS) following viral pneumonia is one of the most common causes of death from ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Femoral neck fracture is the most common form of hip fracture with annual treatment costs in the U.S. estimated to be between $10 to $15 billion, and are expected to rise due to the aging population, with mortality rates of up to 36%. *click for further information about Muscle injury due to total hip ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Acute Radiation Syndrome (ARS) involves severe, potentially lethal damage to the bone marrow’s ability to produce blood cells, as well as to other systems and organs. Severe damage to bone marrow makes victims vulnerable to life-threatening hemorrhage, infection and anemia. ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Bone marrow deficiency refers to a condition in which the hematopoietic stem cells in the bone marrow fail to produce enough, or produce abnormal, red blood cells, white blood cells and platelets. Hematopoietic cell transplantation (HCT), the transplantation of multipotent hematopoietic cells, is a standard treatment in various malignant and non-malignant conditions. Transplant patients are ...